Phase I/II study (UKT-03) of CCNU/temozolomide chemotherapy in addition to radiotherapy as first-line therapy for glioblastoma: Status report
| Autor: | Rolf D. Kortmann, Thomas Hundsberger, Johannes Rieger, Ulrich Herrlinger, M. Weller, J. Schuth, Dorothee Koch, Michael Bamberg |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Oncology
Cancer Research Chemotherapy medicine.medical_specialty Nitrosourea Temozolomide business.industry medicine.medical_treatment medicine.disease Status report Surgery Radiation therapy chemistry.chemical_compound First line therapy Phase i ii chemistry Internal medicine medicine business neoplasms Glioblastoma medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 23:1566-1566 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2005.23.16_suppl.1566 |
| Popis: | 1566 Background: Primary chemotherapy with single agent temozolomide or nitrosourea-based chemotherapy in addition to radiotherapy prolongs survival in patients with glioblastoma. Previous studies ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|